Tarek Yakout Mohamed <br/><br/>
Hairy cell leukemia management and outcome with cladribine (2- chlorodeoxyadenosine) treatment activity and toxicity /  
 العلاج بعقار الكلادريبين ونتائجه فى مرضى سرطان الدم ذو الخلية المشعرة نتائج العلاج والأعراض الجانبية 
Tarek Yakout Mohamed ; Supervised Ola Mohamed Reda Khorshid , Alfred Elias Namour , Mosaad Mahmoud Elgammal 
 - Cairo :   Tarek Yakout Mohamed ,   2013 
 - 98 P. :   charts , facsimiles ;   25cm 
<br/><br/>Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) 
<br/><br/> Hairy cell leukemia (HCL) is rare B- cell lymphoproliferative disorder . Its treatment has evolved from splenectomy with time to failure (TTF) of 19 months to cladribine that increased complete remission (CR) rate to 90% with only small percentage of patients relapsing at 30 months . Cladribine (CDA) is originally administered intravenously as continuous infusion for 7 days 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>Cladribine  Hairy cell leukemia  Subcutaneous